Rights and permissions
About this article
Cite this article
Efalizumab and etanercept cost-effective choices in psoriasis. Pharmacoecon. Outcomes News 479, 11 (2005). https://doi.org/10.2165/00151234-200504790-00033
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504790-00033